Ibogaine derivative
Ibogaine's main metabolite, back in US trials for the first time. Your body turns ibogaine into noribogaine. Developers hope it keeps the benefits with fewer risks — that's still a hope, not a finding.
Not an approved treatment for any condition yet.
One card per condition, strongest evidence first. Hover or tap a label to see what it means; the numbers link to sources at the bottom of the page.
First US trial just cleared. No results.
In April 2026 the FDA allowed a Phase 1 study of noribogaine for alcohol use disorder — the first US study of any ibogaine derivative. That's permission to test, not evidence it works.1
Didn't ease withdrawal in its only trial so far.
In a placebo-controlled safety study in opioid-dependent people, single doses of noribogaine showed only a non-significant trend towards less withdrawal (27 people).2
In an early safety study in people on opioid substitution therapy, noribogaine prolonged the QT interval in a dose-dependent way.2
Before You Call Iboga a PsychedelicWestern medicine is turning iboga into ibogaine. In Gabon, the practice means something else.Read the article 
How Ibogaine Is Helping Veterans Rewire Trauma and Redefine StrengthAn eight-day ibogaine programme helping veterans with PTSD and brain injury process trauma.Read the article 
Personal Breakthrough From Addiction After Psychedelic IntegrationWhy integration, not the substance itself, is what broke one man’s addiction for good.Read the article Research databaseNew studies, summarisedHundreds of papers on psychedelics and mental health, each with a plain-language summary and key facts.Browse the database Numbered in the order they appear above. We only use peer-reviewed papers, official company announcements (for trial status and topline results), regulators and trial registries.
From thought-provoking podcasts and original stories to research breakthroughs and industry news, stay connected to the conversations that matter.
Joined by 12,000+ readers
